Epithelial cell adhesion molecule (EpCAM) functions not only in physiological processes but
also participates in the development and progression of cancer. In recent decades …

Metastatic prostate cancer patients present in two ways—with already disseminated disease
at the time of presentation or with disease recurrence after definitive local therapy. Androgen …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

We report herein the discovery of highly potent PROTAC degraders of androgen receptor
(AR), as exemplified by compound 34 (ARD-69). ARD-69 induces degradation of AR protein …

Proteolysis targeting chimera (PROTAC) small-molecule degraders have emerged as a
promising new type of therapeutic agents, but the design of PROTAC degraders with …

Prostate cancer is the second most common malignancy in men and androgen deprivation
therapy is the first‐line therapy. However, most cases will eventually develop castration …

The androgen receptor (AR) antagonist enzalutamide is one of the principal treatments for
men with castration-resistant prostate cancer (CRPC). However, not all patients respond …

The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …

Prostate cancer (PC), the second most prevalent malignancy in men worldwide, has been
proven to depend on the aberrant activation of androgen receptor (AR) signaling. Long-term …

The widespread application of antiandrogen therapies has aroused a significant increase in
the incidence of NEPC, a lethal form of the disease lacking efficient clinical treatments. Here …